Metadoxine improves the three- and six-month survival rates in patients with severe alcoholic hepatitis

Table 2 Development of complications at the 3-mo follow-up n (%)

Complication	PDN+MTD (n = 35)	PDN (n = 35)	PTX+MTD (n = 32)	PTX (n = 33)	P value2	HR (95%CI)3	P value4	HR (95%CI)5
HE	10 (28.6)	21 (60.0)	13 (40.6)	17 (51.5)	0.0081	0.2 (0.1-0.7)	0.38	0.6 (0.2-1.7)
HRS	11 (31.4)	19 (54.3)	11 (34.4)	16 (48.5)	0.051	0.3 (0.1-1.0)	0.25	0.5 (0.2-1.5)
VB	10 (28.6)	13 (37.1)	11 (34.4)	14 (42.4)	0.44	0.6 (0.2-1.8)	0.51	0.7 (0.2-1.9)
Infections	11 (31.4)	14 (40.0)	11 (34.4)	12 (36.4)	0.45	0.6 (.02-1.8)	0.87	0.9 (0.3-2.5)
None	24 (68.6)	21 (60)	21 (65.6)	21 (63.6)
UTI	0 (0)	3 (8.6)	3 (9.4)	6 (18.25)
SBP	2 (5.7)	2 (5.7)	3 (9.4)	3 (9.15)
Pneumonia	9 (25.7)	7 (20)	1 (3.1)	1 (3.0)
EC	0 (0)	1 (2.85)	3 (9.4)	1 (3.0)
Diarrhea	0 (0)	1 (2.85)	1 (3.1)	1 (3.0)

¹Significant difference (P < 0.05);

²P value comparing the PDN vs the PDN+MTD groups;

³HR and 95%CI comparing the PDN vs the PDN+MTD groups;

⁴P value comparing the PTX vs the PTX+MTD groups;

⁵HR and 95%CI comparing the PTX vs the PTX+MTD groups. EC: Esophageal candidiasis; HE: Hepatic encephalopathy; HR: Hazard ratio; HRS: Hepatorenal syndrome; PDN: Prednisone; PDN+MTD: Prednisone + metadoxine; PTX: Pentoxifylline; PTX+MTD: Pentoxifylline + metadoxine; SBP: Spontaneous bacterial peritonitis; UTI: Urinary tract infection; VB: Variceal bleeding.